OMENN GILBERT S 4

What Happened
Gilbert S. Omenn, a director of Galectin Therapeutics, was granted a derivative award for 60,000 shares (reported as 60,000 shares acquired at $0.00) on January 16, 2026. The grant is an equity award under the company's compensation plan rather than an open‑market purchase or sale; no cash changed hands at grant.

Key Details

• Transaction date: 2026-01-16 (reported on Form 4 filed 2026-01-21).
• Transaction type: Award/Grant (derivative); 60,000 shares reported at $0.00 acquisition price.
• Shares owned after transaction: Not specified in this filing.
• Footnotes: (1) Award issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. (2) Options vest 100% on December 31, 2026.
• Filing timeliness: Filed five calendar days after the transaction; Form 4s are typically due within two business days, so this filing appears later than the usual deadline.

Context
This was a grant of options/equity compensation (not an immediate purchase or sale). The options vest in full at the end of 2026, so they are not immediately exercisable for sale. The Form 4 does not disclose an exercise price or any immediate disposition; such grants are common for director compensation and do not by themselves indicate a buy/sell signal.